Newsfeeds - Spark Newswire

1 minute read

Amicus Therapeutics Q4 Sales $88.10M Beat $86.29M Estimate

Today, 3:59 AM

Amicus Therapeutics (NASDAQ:FOLD) reported quarterly sales of $88.10 million which beat the analyst consensus estimate of $86.29 million by 2.09 percent. This is a 7.23 percent increase over sales of $82.15 million the

FOLD

11 minute read

Earnings

Earnings Scheduled For March 1, 2023

By Benzinga Insights

Today, 3:59 AM

Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million.

AAN

1 minute read

‘I Think You Should Take The Money And Run’: Cramer On This Stock Up 52% Over Past Month

By Lisa Levin

Today, 3:59 AM

On CNBC’s "Mad Money Lightning Round," Jim Cramer said Amicus Therapeutics Inc (NASDAQ: FOLD) is an "ideal spec.

ARRY

1 minute read

Amicus Therapeutics Provides EU Regulatory Update For AT-GAA

By Benzinga Newsdesk

Today, 3:59 AM

Amicus Therapeutics (NASDAQ:FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today provided an EU regulatory update for

FOLD

2 minute read

Amicus Therapeutics Announces Common Stock Offering Of Up To $250M

By Benzinga Newsdesk

Today, 3:59 AM

We have entered into an equity distribution agreement with Goldman Sachs & Co. LLC, or Goldman Sachs, as our sales agent, relating to shares of our common stock offered by this prospectus supplement. In accordance

FOLD

1 minute read

Amicus Therapeutics Q3 EPS $(0.12) Beats $(0.19) Estimate, Sales $81.69M Miss $84.22M Estimate

By Benzinga Newsdesk

Today, 3:59 AM

Amicus Therapeutics (NASDAQ:FOLD) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.19) by 36.84 percent. This is a 36.84 percent increase over losses of $(0.19) per share

FOLD

13 minute read

Earnings

Earnings Scheduled For November 7, 2022

By Benzinga Insights

Today, 3:59 AM

Companies Reporting Before The Bell • NAPCO Security Techs (NASDAQ:NSSC) is expected to report quarterly earnings at $0.13 per share on revenue of $36.34 million.

AAON

6 minute read

Provention Bio’s Second Try, Apellis’s Eye Disorder Drug Review, 3 Adcom Verdicts And More: November’s Key PDUFA Catalysts Biotech Investors Must Know

By Shanthi Rexaline

Today, 3:59 AM

Editor's note: This story has been corrected to reflect that the FDA deferred action on Amicus Therapeutics' Biologics License Application.

APLS

1 minute read

FDA Defers Action On Amicus Therapeutics’ Much Awaited Pompe Disease Therapy

By Vandana Singh

Today, 3:59 AM

The FDA deferred action on Amicus Therapeutics Inc’s (NASDAQ:FOLD) Biologics License Application (BLA) for cipaglucosidase alfa, the biologic component of AT-GAA for…

FOLD

3 minute read

U.S. FDA Defers Action On Filing For AT-GAA In Late-Onset Pompe Disease

By Benzinga Newsdesk

Today, 3:59 AM

FDA Issues Deferred Action Letter on AT-GAA Regulatory Filing Due to the Inability to Conduct Required Manufacturing Site Inspection Prior to the PDUFA Action Date Company is Now Actively Engaged with the Agency to

FOLD